A study recently published in the Journal of the American Medical Association (JAMA) reviewed trends in US premarket review pathways for medtech products from 1976 to 2020 and concluded that the regulatory process has become complex and the path to market for some medical devices tricky.
“Increased [Food and Drug Administration] support from industry and concern about flexible authorization requirements reflect the tension between efficient access and the need for assurances that products will safely benefit patients,”
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?